Hemorrhagic complications of anticoagulant treatment

Chest

Volumn 119, Issue , 2001, Pages 108S-121S

  Levine, M N ^a   Raskob, G ^a   Landefeld, S ^a   Kearon, C ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DALTEPARIN; DANAPAROID; DICOUMAROL; ENOXAPARIN; HEPARIN; INDOBUFEN; NADROPARIN; PHENPROCOUMON; REVIPARIN; TINZAPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART VALVE PROSTHESIS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HEART VALVE PROSTHESIS; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; ISCHEMIC ATTACK, TRANSIENT; MYOCARDIAL ISCHEMIA; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0035128589     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.1_suppl.108s     Document Type: Article

References (164)

1. Hemorrhagic complications of long-term anticoagulant therapy
2. Hemorrhagic complications of long-term anticoagulant therapy
3. Hemorrhagic complications of anticoagulant treatment
4. Hemorrhagic complications of anticoagulant treatment
5. Hemorrhagic complications of anticoagulant treatment
6. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis
7. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement
8. Trial of different intensities of anticoagulation in patients with prosthetic heart valves
9. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves
10. Risk factors for intracranial hemorrhage in outpatients taking warfarin
11. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials
12. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke
13. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation
14. Very low doses of warfarin can prevent thrombosis in central vein catheters: A randomized prospective trial
15. Double-blind randomized trial of very low dose warfarin for prevention of thromboembolism in stage IV breast cancer
16. Risk factors for complications of chronic anticoagulation: A multicenter study: Warfarin Optimized Outpatient Follow-up Study Group
17. Bleeding during antithrombotic therapy in patients with atrial fibrillation
18. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia
19. Bleeding in outpatients treated with warfarin: Relation to the prothrombin time and important remediable lesions
20. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy
21. Duration of warfarin anticoagulation therapy and the probabilities or recurrent thromboembolism and hemorrhage
22. The significance of hemorrhage during treatment of patients with coumarin anticoagulants
23. Bleeding complications to oral anticoagulant therapy: Multivariate analysis of 1, 010 treatment years in 551 outpatients
24. The cause of bleeding during anticoagulant treatment
25. Problems associated with long-term anticoagulant therapy
26. Hemorrhagic complications of anticoagulant therapy
27. Bleeding complications in oral anticoagulant therapy: An analysis of risk factors
28. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT)
29. Major hemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort
30. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism
31. Safety of treatment with oral anticoagulants in the elderly: A systematic review
32. A 7-year analysis of hemorrhage in patients in long-term anticoagulant treatment
33. The performance of clinics for outpatient control of anticoagulation
34. Management of anticoagulation in outpatients: Experience with an anticoagulation service in a municipal hospital setting
35. Age-related risks of long term oral anticoagulant therapy
36. Analysis and occurrence of adverse events with oral anticoagulant therapy
37. Atrial fibrillation and stroke: Three new studies, three remaining questions
38. Prospective evaluation of an index for predicting risk of major bleeding in outpatients treated with warfarin
39. Risk of complications during intravenous heparin therapy
40. Hemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis
41. Major bleeding after hospitalization for deep vein thrombosis
42. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction
43. The Medical Research Council's general practice research framework
44. Fecal hemoglobin excretion in elderly patients with atrial fibrillation: Combined aspirin and low-dose warfarin vs conventional warfarin therapy
45. Experiences with long-term anticoagulant treatment
46. Long-term anticoagulant therapy
47. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy
48. Long-term anticoagulant therapy in patients with cerebral infarction
49. Anticoagulant therapy: Five years experience with the patient with an established cerebrovascular accident
50. An evaluation of anticoagulant therapy in the treatment of cerebrovascular disease: Report of the Veterans Administration Cooperative study of atherosclerosis
51. Anticoagulant therapy in cerebral infarction: Report on cooperative study
52. Anticoagulant therapy in cerebral thrombosis and cerebral embolism
53. A controlled clinical trial of long-term anticoagulant therapy in cerebrovascular disease
54. Cerebrovascular disease: Trial of long-term anticoagulant therapy
55. Anticoagulant vs antiplatelet therapy as prophylactic against cerebral infarction in transient ischemic attacks
56. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin
57. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation
58. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves
59. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: Danger of aspirin compared with dipyridamole
60. Bleeding dining acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement
61. Prevention of arterial thromboembolism with acetylsalicylic acid: A controlled study in patients with aortic ball valves
62. Pharmacologic control of thromboembolic complications of cardiac-valve replacement
63. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement
64. Comparison of high dose with low dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulants
65. AREVA: Multicenter randomized comparison of low dose versus standard dose anticoagulation in patients with mechanical prosthetic heart valves
66. A comparison of a moderate with moderate-high intensity oral anticoagulant treatment in patients with mechanical heart valve prostheses
67. Optimal oral anticoagulant therapy in patients with mechanical heart valves
68. The effect of low dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation
69. Special Report. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study
70. Placebo-controlled randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study
71. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study
72. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation
73. Canadian atrial fibrillation anticoagulation study
74. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial
75. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation
76. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation: SIFA (Studio Italiano Fibrillazione Atriale) Investigators
77. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study
78. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: Randomised controlled trial comparing two intensities of coumarin with aspirin
79. Prevention of thromboembolism in atrial fibrillation: A meta-analysis of trials of anticoagulants and antiplatelet drugs
80. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis
81. Preventing stroke in patients with atrial fibrillation
82. The effect of wartarin on mortality and reinfarction after myocardial infarction
83. A double-blind trial to assess long-term anticoagulant therapy in elderly patients after myocardial infarction
84. Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction
85. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction
86. Secondary prevention of myocardial infarction: A comparison of acetylsalicylic acid, placebo and phenprocoumon
87. Double blind trial of long term anticoagulant treatment after myocardial infarction
88. A double blind trial of long term anticoagulant treatment after myocardial infarction
89. The effect of long term treatment with dicumarol in myocardial infarction
90. Therapeutic level in long term anticoagulant therapy after myocardial infarction: Its relation to recurrent infarction and sudden death
91. Long term anticoagulant therapy after myocardial infarction
92. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction
93. Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis
94. Low dose heparin therapy in the long term management of venous thromboembolism
95. Warfarin sodium versus low dose heparin in the long term treatment of venous thromboembolism
96. Adjusted subcutaneous heparin versus warfarin sodium in the long term treatment of venous thrombosis
97. Low molecular weight heparin versus warfarin: The prevention of recurrence after deep vein thrombosis
98. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: A randomized trial
99. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis
100. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis
101. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism
102. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis
103. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis
104. A randomized trial comparing the activated thromboplastin time with the heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin
105. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
106. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
107. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
108. Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism
109. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
110. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis
111. A meta-analysis comparing low molecular weight heparins with unfractionated heparin in the treatment of venous thromboembolism
112. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: A meta-analysis of randomized controlled trials
113. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism
114. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis
115. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
116. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism
117. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
118. Three months compared with one year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis: The Warfarin Optimal Duration Italian Trial (WODIT)
119. Acetaminophen and other risk factors for excessive warfarin anticoagulation
120. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect
121. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits
122. Management of heparin therapy
123. Randomized prospective trial of continuous vs intermittent heparin therapy
124. Haemorrhagic complications of heparin therapy
125. Heparin therapy: A randomized prospective study
126. Heparin treatment of deep vein thrombosis
127. Heparin therapy in venous thromboembolism
128. An objective study of alternative methods of heparin administration
129. Subcutaneous administration of heparin: A randomized comparison with intravenous administration of heparin to patients with deep vein thrombosis
130. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis: A randomized trial
131. Subcutaneous vs intermittent heparin in the treatment of deep vein thrombosis: A randomized clinical trial
132. The weight-based heparin nomogram compared with a 'standard care' nomogram: A randomized controlled trial
133. Comparison of subcutaneous low molecular weight heparin with intravenous standard in proximal deep vein thrombosis
134. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis
135. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis
136. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial
137. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis
138. One daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis
139. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin
140. Antithrombotic therapy in acute ischemic stroke: An overview of the completed randomized trials
141. Low molecular weight heparin for the treatment of acute ischemic stroke
142. The International Stroke Trial (IST): A randomized trial of aspirin, subcutaneous heparin, both or neither among 19, 435 patients with acute ischemic stroke
143. Low molecular weight heparinoid, ORG10172 (Danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial
144. Aspirin, heparin or both to treat acute unstable angina?
145. Effectiveness of low-dose heparin in prevention of myocardial reinfarction
146. Comparison of high dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction
147. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
148. Low molecular weight heparin during instability in coronary artery disease
149. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary, artery disease: Fragmin in unstable coronary artery disease study
150. Comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease
151. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI IIA
152. Long term low molecular mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicentre study
153. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non Q wave myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) IIB Trial
154. Fixed vs adjusted-dose heparin in the prophylaxis of thromboembolism in spinal cord injury
155. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
156. Hirudin in acute myocardial infarction
157. The hazards of heparin plus aspirin
158. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting
159. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
160. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization
161. Efficacy and toxicity of heparin in relation to age and sex
162. Heparin-induced bleeding
163. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time
164. Aging and heparin-related bleeding